Moreover, a single-site biopsy may not provide a representative profile of the tumor heterogeneity as it is spatially and temporally constrained, and necessitates the development of a non-invasive tool to follow-up AXL expression during and/or after therapy 8, 11. The gene discussed is AXL; the disease is neoplasm.